Franklin Resources Inc. Sells 537 Shares of LivaNova PLC (NASDAQ:LIVN)

Franklin Resources Inc. trimmed its position in LivaNova PLC (NASDAQ:LIVN) by 1.1% in the third quarter, HoldingsChannel reports. The firm owned 49,923 shares of the company’s stock after selling 537 shares during the quarter. Franklin Resources Inc.’s holdings in LivaNova were worth $2,687,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LIVN. Canada Pension Plan Investment Board bought a new position in shares of LivaNova in the second quarter valued at approximately $88,000. Central Pacific Bank Trust Division bought a new position in LivaNova in the 3rd quarter valued at $178,000. TradeLink Capital LLC purchased a new stake in shares of LivaNova during the 2nd quarter valued at $208,000. Captrust Financial Advisors bought a new stake in shares of LivaNova during the 3rd quarter worth $217,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of LivaNova in the 3rd quarter worth about $219,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.5 %

LivaNova stock opened at $46.75 on Thursday. The firm has a 50 day simple moving average of $51.32 and a 200 day simple moving average of $50.92. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 1-year low of $43.15 and a 1-year high of $64.47. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of 111.31 and a beta of 0.98.

Analysts Set New Price Targets

LIVN has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Mizuho dropped their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Finally, StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $69.17.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.